Procept Stock: Biotech leader Procept BioRobotics is breaking out past its latest buy point. Shares jumped on Q1 earnings results Wednesday.
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 7.27% and 6.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 mi